Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease.
Tadbiri S, Nachury M, Bouhnik Y, Serrero M, Hébuterne X, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, ABitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Dib N, Brixi H, Boualit M, Plastaras L, Boivineau L, Fumery M, Caillo L, Laharie D, Amiot A; GETAID-IBD-disk study group. Tadbiri S, et al. Among authors: gilletta c. J Crohns Colitis. 2021 May 4;15(5):766-773. doi: 10.1093/ecco-jcc/jjaa244. J Crohns Colitis. 2021. PMID: 33246337 Free article.
Changes in the Lémann Index Values During the First Years of Crohn's Disease.
Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, Sokol H, Pariente B, Seksik P, Cosnes J. Gilletta C, et al. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1633-40.e3. doi: 10.1016/j.cgh.2015.02.041. Epub 2015 Mar 10. Clin Gastroenterol Hepatol. 2015. PMID: 25766650
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Tadbiri S, et al. Among authors: gilletta c. Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18. Aliment Pharmacol Ther. 2018. PMID: 29250803
Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study.
Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L; CLEAN Study Group. Briot C, et al. Among authors: gilletta c. J Crohns Colitis. 2019 Sep 19;13(9):1121-1130. doi: 10.1093/ecco-jcc/jjz040. J Crohns Colitis. 2019. PMID: 30785181
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A; GETAID-Vedo-STOP Study Group. Martin A, et al. Among authors: gilletta c. J Crohns Colitis. 2020 Jul 30;14(7):896-903. doi: 10.1093/ecco-jcc/jjaa005. J Crohns Colitis. 2020. PMID: 31930285 Free article.
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Pariente B, Fumery M; UC-USK-GETAID Study Group. Amiot A, et al. Among authors: gilletta c. Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046. doi: 10.1111/apt.15717. Epub 2020 Apr 14. Aliment Pharmacol Ther. 2020. PMID: 32291786 Free article.
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.
Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Brazier F, Pouillon L, Flourie B, Boivineau L, Siproudhis L, Laharie D, Roblin X, Diouf M, Treton X. Fumery M, et al. Among authors: gilletta c. J Crohns Colitis. 2020 Sep 8:jjaa177. doi: 10.1093/ecco-jcc/jjaa177. Online ahead of print. J Crohns Colitis. 2020. PMID: 32898232 Free article.
Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group.
Nachury M, Bouhnik Y, Serrero M, Filippi J, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D, Amiot A; GETAID-patient experience study group. Nachury M, et al. Among authors: gilletta c. Dig Liver Dis. 2021 Apr;53(4):434-441. doi: 10.1016/j.dld.2020.10.020. Epub 2020 Nov 10. Dig Liver Dis. 2021. PMID: 33187920 Free article.
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Wils P, Seksik P, Stefanescu C, Nancey S, Allez M, Pineton de Chambrun G, Altwegg R, Gilletta C, Vuitton L, Viennot S, Serrero M, Fumery M, Savoye G, Collins M, Goutorbe F, Brixi H, Bouguen G, Tavernier N, Boualit M, Amiot A, Abitbol V, Laharie D, Pariente B; PREGNANCY-GETAID study group. Wils P, et al. Among authors: gilletta c. Aliment Pharmacol Ther. 2021 Feb;53(4):460-470. doi: 10.1111/apt.16192. Epub 2020 Dec 7. Aliment Pharmacol Ther. 2021. PMID: 33345331
Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
Tannoury J, Nachury M, Martins C, Serrero M, Filippi J, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWitt O, Vuitton L, Mathieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Laharie D, Amiot A; GETAID-Patient Experience Study Group. Tannoury J, et al. Among authors: gilletta c. Aliment Pharmacol Ther. 2021 May;53(10):1098-1107. doi: 10.1111/apt.16353. Epub 2021 Apr 5. Aliment Pharmacol Ther. 2021. PMID: 33817819 Free article.
43 results